Horizon數位前沿主動型ETF YNOT 深 滬
已收盤 05-08 16:00:00 美东时间
32.9304
+0.527
+1.63%
華盛通- 最 高32.9304
- 今 開32.7241
- 成交量 8007股
- 最 低 32.66
- 昨 收 32.4037
- 總市值 1.10亿
- 52周最高 32.96
- 市盈率 靜 --
- 換手率 0.24%
- 52周最低 25.08
- 委 比 0.00%
- 總股本 334.00万
- 歷史最高 32.96
- 量 比 0.56
- 振 幅 0.83%
- 歷史最低 25.08
- 每 手 1
- 風險率 1.53%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Merck Announces FDA Priority Review for KEYTRUDA And KEYTRUDA QLEX, Each In Combination With Padcev, For The Treatment Of Patients With Muscle-Invasive Bladder Cancer, With PDUFA Date Set For August 17
If approved, these indications would expand the use of KEYTRUDA and KEYTRUDA QLEX, each in combination with Padcev, as the first perioperative treatments for patients with MIBC regardless of cisplatin eligibility and
04-20 18:51
FDA grants priority review to Merck’s Keytruda-Padcev for cisplatin-eligible bladder cancer
FDA grants priority review to Merck’s Keytruda-Padcev for cisplatin-eligible bladder cancer FDA granted priority review for Merck sBLA seeking KEYTRUDA, KEYTRUDA QLEX use with Padcev in perioperative treatment of cisplatin-eligible muscle-invasive bladder cancer. PDUFA target action date set for Aug
04-20 18:48
Merck Says EU Approves KEYTRUDA, In Combination With Paclitaxel, With Or Without Bevacizumab, For Treatment Of Platinum-Resistant Epithelial Ovarian, Fallopian Tube Or Primary Peritoneal Carcinoma In Adults
The KEYTRUDA regimen is the first and only PD-1 inhibitor-based treatment approved in the European Union for these patientsApproval supported by data from the Phase 3 KEYNOTE-B96 trial in which the KEYTRUDA regimen
04-02 18:48
EU approves Merck Keytruda-paclitaxel regimen for PD-L1+ platinum-resistant ovarian cancer
EU approves Merck Keytruda-paclitaxel regimen for PD-L1+ platinum-resistant ovarian cancer European Commission cleared Keytruda with paclitaxel, with or without bevacizumab, for adults with PD-L1 CPS ≥1 platinum-resistant recurrent ovarian, fallopian tube, or primary peritoneal cancer. Label covers
04-02 18:46
BRIEF-Eco Wave Power Featured In Nvidia CEO Jensen Huang's Gtc Keynote Highlighting Ai-Driven Coastal Energy Infrastructure
BRIEF-Eco Wave Power Featured In Nvidia CEO Jensen Huang's Gtc Keynote Highlighting Ai-Driven Coastal Energy Infrastructure March 18 (Reuters) - Eco Wave Power Global AB (publ) 1KW0y.F : ECO WAVE POWER FEATURED IN NVIDIA CEO JENSEN HUANG'S GTC KEYNOTE HIGHLIGHTING AI-DRIVEN COASTAL ENERGY INFRASTRUC
03-18 20:33
Pfizer And Astellas Pharma Announce Results From Phase 3 EV-304 Clinical Trial For PADCEVTM In Combination With Keytruda In Patients With MIBC Eligible For Cisplatin-Based Chemotherapy
In the Phase 3 EV-304 trial, statistically significant improvements in overall survival and pathological complete response were also observed, with over half of patients having no detectable disease at surgeryThe
02-27 23:02
FDA Approves Merck's KEYTRUDA Regimen for Platinum-Resistant Ovarian Cancer
FDA Approves Merck's KEYTRUDA Regimen for Platinum-Resistant Ovarian Cancer The U.S. Food and Drug Administration (FDA) has approved Merck & Co. Inc.'s KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph) in combination with paclitaxel, with or without bevaciz
02-11 19:45
Merck's Keytruda gains additional indications for ovarian, fallopian tube carcinoma
The US FDA has approved Merck's oncologic Keytruda (pembrolizumab) to treat platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal carcinoma whose tumors express PD-L1. Keytruda ...
02-11 06:39
Immutep Achieves 50% Participant Enrollment Target In TACTI-004 Phase III Study Evaluating Eftilagimod Alfa In Combination With Merck's Anti-PD-1 Therapy
Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep" or "the Company"), a late-stage immunotherapy company targeting cancer and autoimmune diseases, today announces it has achieved 50% of the patient enrolment target in
02-06 21:04
Moderna Reports Five-Year Data Showing mRNA-4157 and Keytruda Cut Melanoma Recurrence Risk by 49%
Moderna Reports Five-Year Data Showing mRNA-4157 and Keytruda Cut Melanoma Recurrence Risk by 49% Moderna Inc. and Merck have announced median five-year follow-up data from the Phase 2b KEYNOTE-942/mRNA-4157-P201 study, which evaluated adjuvant treatment with intismeran autogene in combination with
01-27 23:57
